BioRestorative Therapies appoints Donald J. Currie to board of directors

BioRestorative Therapies, Inc. appointed Donald J. Currie as a Class I director effective October 7, 2026, filling the vacancy created by the previously reported resignation of Katharyn Field as a director effective August 31, 2026.¹ Currie will serve until the company's 2027 annual meeting of stockholders and until his successor is duly elected and qualified or his earlier death, resignation or removal.¹

The board also named Currie to its Nominating and Corporate Governance Committee and its Compensation Committee, as part of actions taken by the board regarding committee membership.¹ Following the appointment, the board's committees are composed as follows: the Audit Committee includes Steven Brown as chair along with Jatinder Dhaliwal and Esha Randhawa; the Compensation Committee includes Dhaliwal as chair along with Brown, Randhawa and Currie; and the Nominating and Corporate Governance Committee includes Randhawa as chair along with Dhaliwal, Brown and Currie, giving effect to Mr. Currie's appointment.¹

The board determined that Currie qualifies as an independent director under Nasdaq listing rules, including standards for audit and compensation committee members, and under SEC Rule 10A-3.¹

Currie, 65, has been CEO and a director of Hillcrest Energy Technologies Ltd., a company working on power conversion and digital control technology for electric powertrains and renewable energy grid systems, a role he has held since February 2010.¹ He has more than 30 years in the energy sector and in financing public companies in North American equity markets, with background in company formation, corporate strategy and capital raising.¹

The filing states there is no arrangement between Currie and any other person related to his appointment, and no family relationships or reportable related-party transactions involving him.¹ For his board and committee service, Currie will be paid a flat monthly cash fee in Canadian dollars plus expense reimbursement, rather than participating in the company's standard non-employee director pay program, under terms set out separately from the company's regular director compensation arrangements.¹